Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer

Figures & data

Table I. Patients’ characteristics and association with the genotypic distribution of PLA2G4C gene polymorphism (rs 1549637).

	Genotype
Characteristic	T/T	A/A+A/T	p-value
Total number	270	111	0.813
Age, median (range)	72 (29–94)	71 (25–93)	0.169
Sex, men/women	157/113	56/55	0.870
Tumor localization, colon/rectum	146/124	59/52	0.845
Stage, number (%)
1	49 (18)	18 (16)
2	94 (35)	44 (39)
3	85 (31)	33 (30)
4	42 (16)	16 (15)
Excision <12 lymph nodes, no. (%)	140/269 (52)	60/110 (54)	0.658
Low differentiated cancer, no. (%)	61/267 (23)	23/110 (21)	0.681
Mucinous cancer, no. (%)	36/268 (13)	13/110 (12)	0.671
T4 tumor, no. (%)	19/270 (7)	11/111 (10)	0.344
Adjuvant treatment, all stages	70/268 (26)	34/107 (32)	0.269
Adjuvant treatment, stage II	4/94 (4)	2/43 (5)	0.916

Table II. Genotypic and allelic distributions in % (n) of PLA2G4C gene polymorphism (rs 1549637) in patients with CRC and in healthy control subjects.

Genotype	CRC (n = 381)	Controls (n = 618)	Allele	CRC (n = 762 alleles)	Controls (n = 1236 alleles)
T→A
T/T	70.9 (270)	68.9 (426)
			T	84.1 (641)	83.2 (1028)
T/A	26.5 (101)	28.5 (176)
			A	15.9 (121)	16.8 (208)
A/A	2.6 (10)	2.6 (16)

CRC patients versus control subjects: No significant differences.

Figure 1. Kaplan–Meier curve describing cancer-specific survival estimates among CRC patients of all TNM stages according to genotypes of the PLA2G4C gene polymorphism.

Figure 2. Kaplan–Meier curve describing cancer-specific survival estimates among CRC patients TNM stage II according to genotypes of the PLA2G4C gene polymorphism.

Figure 3. Kaplan–Meier curve describing disease-free survival estimates among CRC patients of all TNM stages according to genotypes of the PLA2G4C gene polymorphism.

Table III. Uni-and multivariable analysis of the cancer-specific mortality.

	Univariable			Multivariable
Variable	HR	95% CI	p-value	HR	95% CI	p-value
All stages
Age	1.01	0.99–1.02	0.438	1.03	1.00–1.05	0.021
Male sex	1.13	0.77–1.67	0.524	1.28	0.83–1.97	0.270
Stage
1	ref			ref
2	2.48	0.84–7.30	0.099	1.68	0.56–5.06	0.359
3	6.70	2.37–18.95	<0.001	7.15	2.44–20.93	<0.001
4	42.88	15.22–120.83	<0.001	77.12	25.35–234.60	<0.001
T4-tumor	3.40	2.02–5.73	<0.001	2.23	1.24–4.02	0.008
Low differentiated	2.44	1.63–3.66	<0.001	2.33	1.44–3.75	0.001
Mucinous cancer	0.87	0.48–1.59	0.662	0.97	0.49–1.91	0.923
Rectal vs. colonic	0.92	0.63–1.35	0.667	0.90	0.59–1.37	0.609
<12 lymph nodes	1.42	0.96–2.12	0.081	1.94	1.22–3.10	0.005
Adjuvant chemotherapy	2.36	1.59–3.49	<0.001	0.62	0.36–1.06	0.081
Genotype T/T vs A/A+A/T	1.72	1.17–2.53	0.006	2.31	1.48–3.60	<0.001
Stage II
Age	1.07	1.02–1.13	0.009	1.06	1.00–1.13	0.045
Male sex	1.47	0.58–3.75	0.419	1.70	0.61–4.73	0.311
T4-tumor	2.28	0.53–9.89	0.270	3.25	0.66–16.10	0.149
Low differentiated	2.32	0.86–6.21	0.095	1.86	0.63–5.47	0.261
Mucinous cancer	0.61	0.14–2.64	0.506	0.39	0.05–3.27	0.387
Rectal vs. colonic	1.23	0.50–3.02	0.654	1.37	0.48–3.93	0.553
<12 lymph nodes	2.12	0.70–6.48	0.186	1.90	0.47–7.73	0.368
Adjuvant chemotherapy	1.50	0.20–11.38	0.693	4.25	0.43–41.68	0.214
Genotype T/T vs A/A+A/T	3.84	1.51–9.78	0.005	2.55	0.89–7.29	0.080

Figure 4. Representative immunohistochemical staining of PLA2G4C in cancer and normal tissue from patients with CRC. The PLA2G4C protein expression is present in cancer (A) and in normal (B) epithelial cells. The arrows indicate positive brown staining. Control staining of normal tissue (C) with only the secondary antibody. Magnification, ×20.